Forskolin

Catalog No.S2449 Synonyms: Coleonol

Molecular Weight(MW): 410.5

Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.

Cited by 8 Publications

Eur J Cancer, 2014, 50(7):1310-20

PubMed: 24559688

Development, 2016, 143(12):2103-10

PubMed: 27151951

Gen Comp Endocrinol, 2016, 237:98-108

PubMed: 27570060

Reprod Domest Anim, 2018, 10.1111/rda.13304

PubMed: 30098220

Sci China Life Sci, 2018, 10.1007/s11427-018-9359-8

PubMed: 30159682

Cell Physiol Biochem, 2018, 45(3):1023-1033

PubMed: 29439250

Osteoarthritis Cartilage, 2017, 25(11):1868-1879

PubMed: 28716756

PLoS One, 2017, 12(3):e0173240

PubMed: 28253352

2 Customer Reviews

Eur J Cancer 2014 50(7), 1310-20. Forskolin purchased from Selleck.

Measurement of cAMP accumulation in INS-1 cells. (A) INS-1, or (B) INS-1 transfected with murine GPR109A for 24 h, or (C) INS-1 transfected with human GPR109A for 24 h were incubated in DMEM (2.5 mM glucose) media with or without PTX (100 ng/ml) for 24 h. Cells were then incubated in KRB supplemented with 2.5 mM glucose, 500 μM IBMX, 10 μM forskolin, and with/without 10 or 100 μM NA for 1 h. After lysis with HCl (0.1 M), cells were sonicated and spun. The supernatants were saved for cAMP measurement by ELISA. (D) Reduction of cAMP accumulation in INS-1 and INS-1 cells transfected with GPR109A in the presence of 10 or 100 μM NA. White bar: INS-1 cells, grey bar: INS-1 cells transfected with murine GPR109A; black bar: INS-1 cells transfected with human GPR109A. (∗ and #p < 0.05, ∗ and ##p < 0.001). (n = 5).

Gen Comp Endocrinol, 2016, 237:98-108. Forskolin purchased from Selleck.

Purity & Quality Control

Choose Selective cAMP Inhibitors

Biological Activity

Description

Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.

Targets

Adenylyl cyclase (AC) ^[1]
(A wide variety of cell types)

In vitro

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (G_s)–AC complexes. Activation of _s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of _s-Forskolin potentiation of AC activity. ^[1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HEK293	MX3GeY5kfGmxbjDBd5NigQ>?	MXOxNEDPxE1?	MkHROkBp		Mo\nbY5kemWjc3XzJJBpd3OyaH;yfYxifGmxbjDv[kBwfmW{ZYjwdoV{e2WmIFvMTGw{KGG2IGO0N\|M>	MlHjNlY1OzV2OUi=
Mo-DCs	MWjGeY5kfGmxbjDBd5NigQ>?	MUC1NEDPxE1?	MVqyOQKBkWh?		NUezZXo1eHKxbX;0[ZMhUUxvMkOgdJJw\HWldHnvckBqdiC2aHWgd5Vx\XKwYYThcpQhd2Zieontc5NidiC\|dHnteYxifGWmIF3vMWREe8Li	M3rHZlI3PDF{OUS4
RBMECs	NITHUZFHfW6ldHnvckBCe3OjeR?=	MnHZOeKh\|ryP	NFPMO3QyyqCq		NEXnUmdjdG:la4OgeIhmKFKjY{GgbY5i[3SrdnH0bY9vKGmwZIXj[YQh[nliRV3BVE1KUQ>?	M2HSVlI3OzV6MEO5
INA-6	MnP5R4VtdCCYaXHibYxqfHliQYPzZZk>	Mn3RNE0yODBizszN	M13Se\|cz6oDLaB?=		MXvpcoR2[2W\|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?=	NHnqNmkzPjNyNk[yOC=>
OPM-2	MX7D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NFjUfJIxNTFyMDFOwG0>	M13nR\|cz6oDLaB?=		NHXB[JNqdmS3Y3XzJINmdGxiZHXheIgh\G:\|ZTDk[ZBmdmSnboTsfS=>	M1fmclI3OzB4NkK0
U266	Mnu1R4VtdCCYaXHibYxqfHliQYPzZZk>	NGnTXVExNTFyMDFOwG0>	NF\sZW04OuLCiXi=		M2jCOIlv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5	NGHIZoQzPjNyNk[yOC=>
H929	NH7tdZdE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MnTNNE0yODBizszN	M1jGflcz6oDLaB?=		NFzx[ldqdmS3Y3XzJINmdGxiZHXheIgh\G:\|ZTDk[ZBmdmSnboTsfS=>	NUnlW4VxOjZ\|ME[2NlQ>
RPMI 8226	NVflVYxoS2WubDDWbYFjcWyrdImgRZN{[Xl?	NFfye40xNTFyMDFOwG0>	MmPGO\|LjiImq		NEWzdGJqdmS3Y3XzJINmdGxiZHXheIgh\G:\|ZTDk[ZBmdmSnboTsfS=>	NX\Zb\|hsOjZ\|ME[2NlQ>
MDCK	MoPpSpVv[3Srb36gRZN{[Xl?	M3PzSFExKML3TR?=	M3;3dVI1KGh?	NX3DfWd3TE2VTx?=	NVPkUYkyfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiVFfGMe6zOSCjbnSgR3RITsLi	NF2wNZAzPjJyMkO1Ni=>
MDCK	MmHySpVv[3Srb36gRZN{[Xl?	NV3MOo91OTBiwsXN	NX\1U4RCOjRiaB?=	NFewVnVFVVOR	MVjpcohq[mm2czD0bIUhcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gSm4h[2G3c3XkJIJ6KFSJRj5OtlE>	M17HS\|I3OjB{M{Wy
Spinal cords	NV7FbI9oTnWwY4Tpc44hSXO\|YYm=	NUC0cW4zOcLizszN	MX2zNEBucW5?		Mlfnd5RqdXWuYYTld{BkSU2SIHzleoVtew>?	MnK3NlYyOjZ7Mk[=
BeWo	MoXrSpVv[3Srb36gRZN{[Xl?	MWKyOgKBkc7:TR?=	MoHNNlQwPDhxN{KgbC=>		MUjs[YFleyC2bzDhckBqdmO{ZXHz[UBqdiC2aHWg[ZhxemW\|c3nvckBw\iCxdHjldkBnfXOrb36gcYFzc2W{cx?=	MoT1NlYxPTN3NEm=
bovine oocytes	M{LYTmZ2dmO2aX;uJGF{e2G7	NXzzT4xVOTBywrFOwG0>	NX3Ld3ZOOTMEoHi=		NVLtfIFUcW6qaXLpeJMhfGinIHXm[oVkfCCxZjDOVHBCKGGwZD;vdkBPWFCFIITvJJN1cW23bHH0[UBz\XO3bYD0bY9vKG:oIH3lbY9{cXN?	NYP4RoVFOjZyNUG2NVE>
Caco-2	Ml3aSpVv[3Srb36gRZN{[Xl?	MXiwMlEwOS9zMDFOwG0>	NV7MW3FROjEEoH3pci=>		M3\4UIlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG\|ZTDpckBqdnS{YXPlcIx2dGG{IHPBUXAhdGW4ZXzz	NYHUOoZ2OjZyNEmxNFI>
Caco-2	Mlj6SpVv[3Srb36gRZN{[Xl?	NVPYXYVvOC5zL{GvNVAh\|ryP	NEn2W40zPCCq		MXHpcoNz\WG\|ZYOgUXJROiCycn;0[YlvKGyndnXs	M2TtSVI3ODR7MUCy
AML-12	M4rQWmZ2dmO2aX;uJGF{e2G7	NIfNVW0zOCEQvF2=	NEHLeoM{KGh?		MV\1dJJm\3WuYYTld{B1cGVicHjvd5Bpd3K7bHH0bY9vKGyndnXsd{BifCCWaIKtOFEyKGGwZDDT[ZIuPDl\|	NFi2Z2MzPjB2OEm4OS=>
AML-12	NE\LfoNHfW6ldHnvckBCe3OjeR?=	MmjzNlAh\|ryP	MX2xMVghcA>?		M4Prd4lv[3KnYYPld{BodHWlb4PlJJBzd2S3Y4Tpc44>	M4\US\|I3ODR6OUi1
AML-12	MmnoSpVv[3Srb36gRZN{[Xl?	MkDhNlAh\|ryP	NH3ocpo{KGh?		M3f5T5VxNXKnZ4XsZZRme8LiUHfjNYEtyqCSZYDjb{wh[W6mwrDHOpBkyqCvUl7BJIxmfmWucx?=	NYfSVHg2OjZyNEi5PFU>
AML-12	NEO1cnNHfW6ldHnvckBCe3OjeR?=	M1HqflIxKM7:TR?=	MWCzJIg>		MVzpcoR2[2W\|IITo[UBl\XCqb4PwbI9zgWyjdHnvckBw\iCFUmTDNuKh	M3vGRVI3ODR6OUi1
RBMECs	NGrYbpBHfW6ldHnvckBCe3OjeR?=	MnXiOeKh\|ryP	MVuxJIg>		MnrhbY5pcWKrdIOgSW1CWC2LST3pcoR2[2WmIHnuZYN1cX[jdHnvckBw\iCUYYCxxsA>	NXjOVG1EOjZyNES2OlM>
EndoC-βH1	NX[5V5VlTnWwY4Tpc44hSXO\|YYm=	NEX4c2Q2yqEQvF2=	NGq5XWsyKGh?		NXLDbm8xeG:2ZX70bYF1\XNiZ3z1Z49{\S2rbnT1Z4VlKGmwc4XsbY4he2WlcnX0bY9vKGmwIITo[UBxemW\|ZX7j[UBw\iCpbIXjc5Nm	MXyyOlAzQDV4Mh?=
EndoC-βH1	M{\6bWZ2dmO2aX;uJGF{e2G7	NET6dGE2yqEQvF2=	MYSxJIg>		NWj0XFNNdGWjZIOgeI8h[SC\|dILvcoch[0GPUDDpcoNz\WG\|ZR?=	MUWyOlAzQDV4Mh?=
SH-SY5Y	NIL1XIxHfW6ldHnvckBCe3OjeR?=	NVS3THdPOzBizszN	NV36c\|ZLOzBibXnu	NVTjVHA1TE2VTx?=	MUHzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgZYN1cX[jdHnvckBw\iCSS1G=	NFfIfIozPjB{NUGzOy=>
PC-3	NXfoWIhRTnWwY4Tpc44hSXO\|YYm=	Mn:0OFAhyrWP	NEnXUoIzKGh?	NHLlRXdFVVOR	M1LsWoxm[WS\|IITvJHBROkFiYXP0bZZifGmxbh?=	M4XGWlI3ODJ\|OEO2
PC-3	NXvoUHNMS2WubDDWbYFjcWyrdImgRZN{[Xl?	M3v2OFQxKML3TR?=	NWjCV3ozOjRxNEivO\|IhcA>?	NGr6PZFFVVOR	NXS4eoFS\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJRqdWViZHXw[Y5l\W62bIm=	MlvvNlYxOjN6M{[=
SCG	NXrjPJZrTnWwY4Tpc44hSXO\|YYm=	NW\hco85OjBizszNxsA>		NVvK[\|ExTE2VTx?=	MkTOdoV3\XK\|aXLsfUB{fXCycnXzd4V{KEmNVjD3bZRpKGFiSVO1NEBw\iB{ND60JO69VQ>?	MnXMNlU6PjJzM{K=
HEK-293	M4K3OWZ2dmO2aX;uJGF{e2G7	MlfVN\|Uh\|ryPwrC=		NILoc21FVVOR	NWSwWpFXcW6mdXPld{BiKGOxboPwbYN2d3W\|IPMAoIlv[WO2aY\heIlwduLCnTDv[kB1cGViS4[yMlEh[3W{cnXueC=>	NVOyeoMzOjV7NkKxN\|I>
SCG	M3\6RmZ2dmO2aX;uJGF{e2G7	NFvqPIIyODBizszNxsA>		NELneoxFVVOR	NFXMPHFz\WS3Y3XzJJRp\SCneHPpeIFjcWyrdImgc4YhW0OJIH7leZJwdnN?	NYHjcYJrOjV7NkKxN\|I>
PCCL3	MYXGeY5kfGmxbjDBd5NigQ>?	M2SzZVExKML3TR?=	NIDoRVQzPCCq		NE\5S49mdmijbnPld{BFfU:6MjDwdo9ud3SncjD0doFve2O{aYD0bY9vKGGldHn2bZR6yqEkgJu=	NH24VpczPTl4MEm1Oi=>
3T3-L1 preadipocytes	Ml23SpVv[3Srb36gRZN{[Xl?	NGXWOHAyOCEQvF5CpC=>	MnH0NVIhcA>?		NInvXJRqdmS3Y3XzJGNTTUJicHjvd5Bpd3K7bHH0bY9vKGGwZDDDM2VDWM7{IHX4dJJme3Orb36=	MojqNlU6OjhyNUi=
H295R	MXTGeY5kfGmxbjDBd5NigQ>?	NH:zblIyOMLizszN	M4\pc\|Q5yqCq		Mli4bY5kemWjc3XzJJN1\XKxaXSgcYV1[WKxbHn0[ZMhcW5idHjlJIFv\HKxZ3XuMEBucW6ncnHsc{0h[W6mIHfseYNw[2:{dHnjc4llKHCjdHj3ZZl{	NUjtTmFDOjV6Nkm1OVY>
PBMC	NUDXeWxCTnWwY4Tpc44hSXO\|YYm=	M3jWdlUxyqEQvF2=	NFm4WIkzPMLiaNMg		NWmwXmNpcW6qaXLpeJMhfGinIHnuZ5Jm[XOnZDDz[YNz\XSrb36gc4YhXE6IIHnu[JVk\WRiYomgeIhmKESSRR?=	M2nDe\|I2QDZ4MEe5
GLUTag	MlTBSpVv[3Srb36gRZN{[Xl?	M1vOO\|Ex6oDLwsXN	MoWzNE8zNzRiaB?=		MWfzeIlufWyjdHXzJGdNWC1zIIPlZ5JmfGmxbjDjc5Rz\WG2ZXSge4l1cCCLQl3Y	M{HzRlI2QDN{NkOx
GLUTag	MYHGeY5kfGmxbjDBd5NigQ>?	M1S4PVEx6oDLwsXN	M3u1ZVQhcA>?		Mo\abY5kemWjc3XzJJRp\SCyQ2LFRkBt\X[nbIOge4l1cCC2aHWgTWJOYA>?	MYiyOVg{OjZ\|MR?=
BAECs	MlXlSpVv[3Srb36gRZN{[Xl?	NF3KVHQzPSEQvF2=	MV2yOEBp		NUnSVHd3\W6qYX7j[ZMhfGinIHHjeIl3[XSrb36gc4YhWFCDUt8xJIJ6KDVizszNJJJme3[ncnH0do9tNCCWNFjTMEBweiB2LWDBVC=>	NH;FTWQzPTd7OEiyOi=>
PC12	MoKxSpVv[3Srb36gRZN{[Xl?	MVmyOeKh\|ryP	NHfSUmk1QCCq		MmPwZYN1cX[jdHXzJINCVVB?	MV:yOVc3QTNyNR?=
GH3	Mlq3SpVv[3Srb36gRZN{[Xl?	NHHuT\|MyyqEQvF2=	NVPm[ZZYPi2q		NEDWOZBifHSnboXheIV{KHSqZTDjc5Jz\WyjdHnvckBj\XS5ZXXuJHBTVCCjbnSgRo1idDFiZYjwdoV{e2mxbh?=	NXrO[WR1OjV5MkewNVg>
GH3	NWDifIc{TnWwY4Tpc44hSXO\|YYm=	NH;se4oyyqEQvF2=	M{ixUVYucA>?		M3\5S4lv\HWlZYOgVHJNKGGwZDDCcYFtOSxiYoX0JI5wfCCFbH;jb{whdVKQQTDlfJBz\XO\|aX;u	MUWyOVczPzBzOB?=
BeWo	NIHteZpHfW6ldHnvckBCe3OjeR?=	NFvpfmsyOOLCit88UeKh	MoLyO\|IhcA>?	M3K1[GROW09?	NX7l[pVQdWWmaXH0[ZMhSmWZbzDj[YxtKGSrZn\ldoVvfGmjdHnvci=>	MmKwNlU4OTN2MkW=
oocytes	NGfUUHhHfW6ldHnvckBCe3OjeR?=	NFS0VG42KM7:TR?=	M1nCfFI1KGh?		NHPEeZlifHSnboXheIV{KHKqLXnud5VtcW5iYXP0bY9vKG:wIH;vZ5l1\SCJVlLEJJNq\26rZnnjZY51dHoEoB?=	MXSyOVcxPzh3NB?=
SC	NWrINJdFTnWwY4Tpc44hSXO\|YYm=	MkjvNE42KM7:TR?=	M3:yXFI1KGh?		M3PzfY1qdWmla4OgeIhmKGWoZnXjeEBw\iClQV3QJIFv[WyxZ4Ogc44hVzFiYX7kJG1DWCCneIDy[ZN{cW:w	NWq5UYxuOjV5MEW4O\|Q>
SC	MXnGeY5kfGmxbjDBd5NigQ>?	MUOwMlUh\|ryP	NHfheFg4OiCq		M4jyOIlv[3KnYYPld{Bjd3SqIFvyc5guOjBiYX7kJG8yKGW6cILld5Nqd25iaX6gZZhwdi2{ZXzheIVlKFOFczDieZQhd26ueTDLdo95NTJywrC=	NGn5NoMzPTdyNUi3OC=>
UACC-647	Mom5SpVv[3Srb36gRZN{[Xl?			NETUdW9FVVOR	M3f1Toxm[WS\|IITvJIEhemm\|ZTDpckBkSU2SIHzleoVteyBqRVO1NOKhRcLiMkCuN\|nDqM7:TTm=	M1zKUFI2PzB\|MEK1
UACC-647	M{HKUWZ2dmO2aX;uJGF{e2G7	NH;ZWWYyOMLizszN	NFzYdFcyPSCvaX6=	NUjmVYh7TE2VTx?=	Ml[3bY5pcWKrdIOgSXJMKHCqb4PwbI9zgWyjdHnvci=>	NUjSTIpZOjV5MEOwNlU>
UACC-647	MVPGeY5kfGmxbjDBd5NigQ>?	MUSxNOKh\|ryP	NHrFdJEyPSCvaX6=	NXLXOWhbTE2VTx?=	NXvDWItscW6lcnXhd4V{KGWHRkKgdIhwe3Cqb4L5cIF1cW:wIHzleoVte8Li	MXeyOVcxOzB{NR?=
SH-SY5Y	NXXSTGxtTnWwY4Tpc44hSXO\|YYm=	MknNNVDDqM7:TR?=	M3e3TVHDqGkEoB?=		MWnpcoNz\WG\|ZYOgUHVEKGGldHn2bZR6	NWrtUY92OjV3OUe0N\|M>
SH-SY5Y	MXLGeY5kfGmxbjDBd5NigQ>?	M4[4clExyqEQvF2=	MVWxxsBpyqB?		NVrBSlZicW6lcnXhd4V{KEGJQ{GgcXJPSSCuZY\lcC=>	MVOyOVU6PzR\|Mx?=
hADSCs	NU\BW3FuTnWwY4Tpc44hSXO\|YYm=	MWm15qCKyrWP	NE\X[GE{OCCvaX6=		NHHxOpNqdmO{ZXHz[ZMh[0GPUDDs[ZZmdHN?	MXWyOVU6OTlyOB?=
HEK293	MYjGeY5kfGmxbjDBd5NigQ>?	MoTHOgKBkcL3TR?=	MWSzNEBucW5?		MVPpcoNz\WG\|ZYOgZ2FOWCCuZY\lcJM>	MlLBNlU2QTF7MEi=
3T3-L1	MmDmSpVv[3Srb36gRZN{[Xl?	NH7WZlgzNjVxNTFOwG0>	NXHWOlIyOjRiaNMg		NHe0coV{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDBWGdNKHC{b4TlbY4h\XiycnXzd4lwdiCjdDDhcIwh\G:\|ZYOgeIV{fGWm	NEnIOW8zPTV7MEW5Oy=>
OCI-Ly1	NI[3T49HfW6ldHnvckBCe3OjeR?=	MkDaOFDDqM7:TR?=	MVKxxsBpyqB?	M{G4N2ROW09?	M37y[4lv\HWlZYOgeIhmKGmwY4LlcYVvfCCxZjDjRW1RKGOxbnPlcpRz[XSrb37z	Mo\pNlU2PzZ{MkC=
OCI-Ly18	M2rwRmZ2dmO2aX;uJGF{e2G7	NYKwc4JnPDEEoN88US=>	M2[1c\|HDqGkEoB?=	MnjoSG1UVw>?	NXq0[XBPcW6mdXPld{B1cGViaX7jdoVu\W62IH;mJINCVVBiY3;uZ4VvfHKjdHnvcpM>	M{i0eFI2PTd4MkKw
BeWo	M3e4T2Z2dmO2aX;uJGF{e2G7	NXfpWY54OjEEoNM1US=>	MWO0POKhcA>?	MnvTSG1UVw>?	MVjpcoNz\WG\|ZYOgeIhmKGSrZn\ldoVvfGmjdHnvckBw\iCEZWfvJINmdGy\|	M2K0clI2PTZ4N{Sw
BeWo	NEHpeIZHfW6ldHnvckBCe3OjeR?=	M{LSTlIxyqEEtV2=	NYfIWWNpPDkEoHi=	MV\EUXNQ	MWLpcoNz\WG\|ZYOgeIhmKGGmaHXzbY9vKG:oIGTIVE0yKG2xbn;jfZRmew>?	MXeyOVU3Pjd2MB?=
LNCaP	NUnjVVNKTnWwY4Tpc44hSXO\|YYm=	MorUNVDDqM7:TR?=	NH;DeWYyOiCqwrC=	NF7xb\|ZFVVOR	NVHiPZVGcW6mdXPld{BiKGS{YX3heIlkKGmwY4LlZZNmKG:oIFPSSWIyKGGldHn2bZR6	M37pXlI2PTR6MEm5
ThGCs	MorpSpVv[3Srb36gRZN{[Xl?	MWKxNQKBks7:TR?=	MWK05qCLcA>?		MYrheYdu\W62czDITWYySSCuZY\lcJMhfGijdDD3[ZJmKHO2aX31cIF1\WRiYomgR49EdDJ?	NFexfFkzPTR\|M{CyOy=>
ThGCs	NVq1fmtUTnWwY4Tpc44hSXO\|YYm=	M4nLd\|Ex6oDMzszN	MVu05qCLcA>?		MlLpbY5kemWjc3XzJGNwS2x{LXnu[JVk\WRiRVTONuKh\2WwZTDlfJBz\XO\|aX;u	Mlq0NlU1OzNyMke=
ThGCs	MWnGeY5kfGmxbjDBd5NigQ>?	M1nWfFEx6oDMzszN	NIfIcoY{KGh?		NVHSeoY4cW6qaXLpeJMhfGinIHXm[oVkfCCxZjDINm8zKG:wIFXEUlIhdVKQQR?=	NGC2R4UzPTR\|M{CyOy=>
RBMECs	MmezSpVv[3Srb36gRZN{[Xl?	MYGwMlA2NzBwNT:1JO69VQ>?	MmDzNE4zPSCq		NVuzVHlXcW6lcnXhd4V{KGODTWCgZ49v[2WwdILheIlwdg>?	MVOyOVQyPjZ3MR?=
RBMECs	NUfLRoU2TnWwY4Tpc44hSXO\|YYm=	MkTUOeKh\|ryP	NX;rXoo{OSCq		MX;icI9kc3NidHjlJIFkfGm4YYTpc44hd2ZiUnjvRU9TV0ONIHnu[JVk\WRiYomgSW1CWC2LSR?=	M3HSUlI2PDF4NkWx
RBMECs	MXrGeY5kfGmxbjDBd5NigQ>?	MnrwOeKh\|ryP	MVqxJIg>		NH7qSZlxemW4ZX70d{B1cGViRV3BVE1KUS2rbnT1Z4VlKFSHRWKgeoFtfWViZHXjdoVie2V?	NGrNZYYzPTRzNk[1NS=>
RBMECs	NUDCPHBlTnWwY4Tpc44hSXO\|YYm=	Mo\SOeKh\|ryP	MUOxJIg>		NGjUdG5xemW4ZX70d{B1cGViaX7jdoVie2ViaX6gTHJRKG[udYigZYNzd3O\|IITo[UBDXEJiaX7keYNm\CCkeTCgSW1CWC2LSR?=	M2XwblI2PDF4NkWx
RBMECs	NVHkbFJJTnWwY4Tpc44hSXO\|YYm=	NVH3UYN4PcLizszN	NF3FVIIyKGh?		NWnRfnVocW6qaXLpeJMhfGinIHTlZ5Jm[XOnZDDv[kBidW:3boSgc4YhYk9vMTDpckBOTnNiaX7keYNm\CCkeTDFUWFRNUmL	MnP4NlU1OTZ4NUG=
RBMECs	NXPEepFvTnWwY4Tpc44hSXO\|YYm=	Mne4OeKh\|ryP	NELQSIoyKGh?		NYr6dYw{emW4ZYLz[ZMhfGinIHPoZY5o\XNiaX6gXm8uOSCmaYP0doljfXSrb36gd4VmdiC5aYToJGVOSVBvSVmgeJJm[XSvZX70	NHjFeGEzPTRzNk[1NS=>
RBMECs	M13zemZ2dmO2aX;uJGF{e2G7	Ml\sOeKh\|ryP	M2f2VlEhcA>?		Mom5Zoxw[2u\|IITo[UBGVUGSLVnJMYlv\HWlZXSgZ4hidmenIHnuJG1NSyCyaH;zdIhwenmuYYTpc44>	M1HNU\|I2PDF4NkWx
RBMECs	Mme2SpVv[3Srb36gRZN{[Xl?	NFXITlI2yqEQvF2=	MYOxJIg>		NVjydlR5[myxY3vzJJRp\SCjY4TpckBkgXSxc3vlcIV1d25icnXhdpJidmenbXXueEB{\WWwIIfpeIghTU2DUD3JTUB1emWjdH3lcpTDqA>?	NHXwe3YzPTRzNk[1NS=>
Primary bovine chondrocytes	Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2m2VVXPxE1?	NVvrbHBtPDhiaB?=		Mn7UdoV3\XK\|ZYOgeIhmKGmwaHnibZRwenliZX\m[YN1KG:oIHPlcIVkd3irYjDvckBxem:uaX\ldoF1cW:wIHnuJIdzd3e2aDDwcIF1\SClaH;u[JJw[3m2ZYO=	NUnFc\|JZOjV2ME[wNVY>
EM1	NYrvNZZbTnWwY4Tpc44hSXO\|YYm=	MmG2NVXjiIsQvF2=	NHjKN\|A1QCCq		NWHmV\|hmemWmdXPld{B1cGViZYjwdoV{e2mxbjDv[uKhVEmIwrDvduKhWFSJU{NCpIlvyqCFQVzSMUBwesLiRWDBR\|Iue2muZX7j[YQhTU1zIHPlcIx{yqB?	NHHsUHIzPTN5OE[2NS=>
BeWo	NXzBTJozTnWwY4Tpc44hSXO\|YYm=	NYPqcoMyOjEEoNM1US=>	NU\zTnhEPDkEoHlCpC=>	Mom4SG1UV8Li	MYTpcoNz\WG\|ZYOgeIhmKGKndHGtbGNIKHKnbHXhd4U>	NGqyNHAzPTN4MkK2NC=>
BeWo	Mn74SpVv[3Srb36gRZN{[Xl?	MkPjNlDDqML3TR?=	M2niVlQ5yqCqwrC=	NUXSdm5ITE2VT9Mg	M{LDfIRwf26{ZXf1cIF1\XNidHjlJIxmfmWuIH;mJHROTU2IMU[=	MYiyOVM3OjJ4MB?=
BeWo	NWHYTWxNTnWwY4Tpc44hSXO\|YYm=	MoPDNlDDqML3TR?=	NVPHOnVzPDkEoHlCpC=>	M3\ldGROW00EoB?=	Ml33[I94dnKnZ4XsZZRmeyC2aHWgcIV3\Wxib3[gS2NONTF?	NVPPeppnOjV\|NkKyOlA>
granulosa cells	NVnuOFFZTnWwY4Tpc44hSXO\|YYm=	MWexNEDPxE1?	MYqxNk8zPCCq		MWTpcoNz\WG\|ZYOgeIhmKGyndnXsd{Bw\sLiUlfTNuKhdVKQQR?=	NGPITmMzPTN\|OUGwOS=>
granulosa cells	NITidlhHfW6ldHnvckBCe3OjeR?=	MX6xNEDPxE1?	NFHzdokyOi9{NDDo		NIHsV5hqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDy[ZBwenSncjDhZ5Rqfmm2eTDmc5IhfGinIHzvcodme3RiZoLh[41mdnRiKPMIllg2PC9tMUjSS3MzNkyXQzm=	M1vSV\|I2OzN7MUC1
granulosa cells	NHi5[npHfW6ldHnvckBCe3OjeR?=	NUXsXXFCOTBizszN	MkjxNlQhcA>?		MVjpcoNz\WG\|ZYOgeIhmKGmwdHXud4l1gSCxZjDEUmEweHKxdHXpckBkd22ybHX4	MkDyNlU{OzlzMEW=
granulosa cells	MVPGeY5kfGmxbjDBd5NigQ>?	M1PlT\|ExKM7:TR?=	MkPNNlQhcA>?		NHjPSYFqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDSS3MzKHC{b33veIVzKGGldHn2bZR6	MmjMNlU{OzlzMEW=
SK-N-AS	M{D1TmNmdGxiVnnhZoltcXS7IFHzd4F6	Mmr1NVAh\|ryPwrC=	M3rJSVI1NzR6IHi=		NHy0boxmdmijbnPld{B1cW2nLXTldIVv\GWwdHz5JINmdGy3bHHyJJZq[WKrbHn0feKh	M3PFRlI2OjZ4ME[z
SK-N-AS	NYrDN4F5TnWwY4Tpc44hSXO\|YYm=	NXfwbZN5OTBizszNxsA>	NETNdGszPCCq		NVLOSlhvcW6lcnXhd4V{KHSqZTDjRW1RKGyndnXsd:Kh	MU[yOVI3PjB4Mx?=
SK-N-AS	M1LDV2Z2dmO2aX;uJGF{e2G7	MUSxNEDPxE4EoB?=	MW[yOEBp		MnK3bY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIN6[2yrbjDENS=>	NHrOeVQzPTJ4NkC2Ny=>
SK-N-AS	NUXOUXF7TnWwY4Tpc44hSXO\|YYm=	MU[xNEDPxE4EoB?=	NHnnTYE{OCCvaX6=		M2XtbIlv\HWlZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJO6zNWOjdHXubY4hMHOnck[3OUktKHBvR2PLN:6zKCi\|ZYK5LUBidmRiY3;uZ49ucXSjboSgbIlocGW{IHzleoVteyCxZjDhZ5RqfmVuIIXudIhwe3Cqb4L5cIF1\WRuIN8yMYNifGWwaX6=	MnLFNlUzPjZyNkO=
SK-N-AS	MoXRSpVv[3Srb36gRZN{[Xl?	M4[3XFExKM7:TdMg	MY[xNE8{OC94MDDtbY4>		MX3pcoNz\WG\|ZYOgcIV3\Wy\|IH;mJJAu\|rJvY3H0[Y5qdiBqc3XyOlc2MSCjbnSgbY5lfWOnczDhZ4N2dXWuYYTpc44hd2ZicD5Otk1k[XSnbnnuJEh{\XJ4N{WpJIlvKCiyZYLpLY52[2ynYYKgdoVocW:wcx?=	MWqyOVI3PjB4Mx?=
SK-N-SH	MljtR4VtdCCYaXHibYxqfHliQYPzZZk>	M2nDeVExKM7:TdMg	Mm\kOFghcA>?		NELZNpRmdmijbnPld{BUUy2QLWPIJI5mfXKxYnzhd5RwdWFiY3XscEB3cWGkaXzpeJk>	MlvrNlUzPjZyNkO=
HEK‐CFTR	MWDGeY5kfGmxbjDBd5NigQ>?	NF[4b5Ez6oDVNUFCpO69VQ>?	NWX0XlJ5OC1zMjDtbY4>	NYqwSGZuTE2VT9Mg	NX74dVFNcW6mdXPld{BiKGSxc3ZihLBl\XCnbnTlcpQhcW:maXTlJIVn\my3eNMg	M1;odVI2OjZ\|MkC3
L6	NIDxPYtHfW6ldHnvckBCe3OjeR?=	MojCOFAhyrWP	Mn7MNlQhcA>?		NVqzO\|RicW6qaXLpeJMhTE2KMT3pcoR2[2WmIFHreEBi[3SrdnH0bY9v	M{W1clI2OjR5NUWw
MIN6	Mk\ESpVv[3Srb36gRZN{[Xl?	MkPCNVAh\|ryPwrC=	MXKzJIg>		NYe1T5BVcW6lcnXhd4V{KER\|IH3SUmEh\XiycnXzd4lwdg>?	NIDXPGgzPTJ2MUGyOC=>
ventricular cardiomyocytes	Mk\4SpVv[3Srb36gRZN{[Xl?	NXLifmFkOC5yMT2xNEDPxE1?			MlHSbY5kemWjc3XzJEBkSU2SIHHjZ5VufWyjdHnvci=>	MXeyOVIxOzFzMx?=
ventricular cardiomyocytes	MoDGSpVv[3Srb36gRZN{[Xl?	NVjWUnI4OC5yMT2xNEDPxE1?			NHf6cYJmfm:tZYOgZY4hcW6xdILvdIlkKHKnc4DvcpNmKDF{MNMxNVUmKGGkb4\lJIJie2GuIIfpeIgh[W5iRVO1NOKhd2ZiMj6yJOK2VQ>?	MUKyOVIxOzFzMx?=
BeWo	MVjGeY5kfGmxbjDBd5NigQ>?	NIPsbFMzOCEEtV2=	NFi0SYs1QCCq	NUnqN5U3TE2VT9Mg	MULpcoR2[2W\|IHPlcIwh\nW\|aX;u	NFiyT2wzPTF6NES3Oy=>
THP-1	M2LRNWZ2dmO2aX;uJGF{e2G7	NEO2cHQyNzFyIN88US=>	M4nLeVLDqGh?	NWrDSnI1TE2VT9Mg	MUHzeZBxemW\|c3XzJG1EWC1zIIDyc4R2[3Srb39CpC=>	NELTZYIzPTF3NEi4Ni=>
Huh-7	NH7LTndHfW6ldHnvckBCe3OjeR?=	MnfTNE0zOCEQvF2=	MX6yJIjDqA>?		MWfy[ZN2dHS\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgbY5kemWjc3WgbY4h[y2PeXOg[ZhxemW\|c3nvckBifCC2aHWgdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdHN?	MmfzNlUyODl6M{S=
C6	MXXGeY5kfGmxbjDBd5NigQ>?	M4LY[lExKM7:TdMg	NEnTV3QzOCCvaX6=		MnPQbY5kemWjc3XzJINCVVBiYXPjeY12dGG2aX;u	NIfzSlgzPTB4OUSxOy=>
SW480	M3SwTmZ2dmO2aX;uJGF{e2G7	MWW0NOKh\|ryP	M2jWOVQ5yqCq	NHX3WYlFVVOR	NHX4dFNi[3SrdnH0[ZMhWFB{QR?=	NH7pb\|kzPDl7N{S1NS=>
HT-29	NWq3N5dtTnWwY4Tpc44hSXO\|YYm=	NUTCeVJMPDEEoN88US=>	MXS0POKhcA>?	MkP5SG1UVw>?	MmHZZYN1cX[jdHXzJHBROkF?	NHvMdJUzPDl7N{S1NS=>
SW480	M13X[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\6eVQxyqEQvF2=	M{XicVAuPzJiaB?=	NGK0ZmpFVVOR	MkSzbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=>	MkHrNlQ6QTd2NUG=
HT-29	NHLqbmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljGOFDDqM7:TR?=	MUmwMVczKGh?	NWn5V4hPTE2VTx?=	MlLobY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=>	NIPQelUzPDl7N{S1NS=>
SW480	NEjxR5dHfW6ldHnvckBCe3OjeR?=	MW[0NOKh\|ryP	M3HBS\|ch\A>?	NX:wc2NKTE2VTx?=	NYfGRnZjemWmdXPld{Bkd2yxbn;zdIhmemViZn;ycYF1cW:wIHPhdIFjcWyrdIpCpC=>	NGT5eYMzPDl7N{S1NS=>
HT-29	MVrGeY5kfGmxbjDBd5NigQ>?	NFO0e3U1OMLizszN	Mn;vO{Bl	MlHXSG1UVw>?	M4qyZ5Jm\HWlZYOgZ49td26xc4Do[ZJmKG[xcn3heIlwdiClYYDhZoltcXS7wrC=	Mm\zNlQ6QTd2NUG=
SW480	NH\qd2VCeG:ydH;zbZMhSXO\|YYm=	MWS0NOKh\|ryP	M4[zRlQ5yqCq	M17YfGROW09?	M{G3Nolv\HWlZYOgZY4h[WO2aY\heIlwdiCxZjDjZZNx[XOnIEOvOy=>	MX2yOFk6PzR3MR?=
HT-29	M{DtXWFxd3C2b4Ppd{BCe3OjeR?=	NEDWdms1OMLizszN	NIT4[G41QMLiaB?=	M4TEc2ROW09?	MmO4bY5lfWOnczDhckBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMz:3	NGPyWXMzPDl7N{S1NS=>
SW480	MkGwRZBweHSxc3nzJGF{e2G7	NVr3eXRvPDEEoN88US=>	NFvPcFg1QMLiaB?=	NFy0UoZFVVOR	MX;pcoR2[2W\|IHPoZY5o\XNiaX6geIhmKHCqb4PwbI9zgWyjdHnvckB{fGG2dYOgc4YhWFB{QTD0ZZJo\XS\|	NXXhSIJpOjR7OUe0OVE>
HT-29	NFf6eIJCeG:ydH;zbZMhSXO\|YYm=	M1TqeVQxyqEQvF2=	NGn3NWM1QMLiaB?=	M{H3[GROW09?	MnnFbY5lfWOnczDjbIFv\2W\|IHnuJJRp\SCyaH;zdIhwenmuYYTpc44he3SjdIXzJI9nKFCSMlGgeIFz\2W2cx?=	M{LDPFI1QTl5NEWx

... Click to View More Cell Line Experimental Data

Protocol

References

Solubility (25°C)

In vitro	DMSO	82 mg/mL (199.75 mM)
	Ethanol	37 mg/mL (90.13 mM)
	Water	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Forskolin SDF

Molecular Weight	410.5
Formula	C₂₂H₃₄O₇
CAS No.	66575-29-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	Coleonol

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00864578	Withdrawn	Primary Open Angle Glaucoma\|Intraocular Pressure	Sooft Italia	April 2009	--
NCT00863811	Withdrawn	Primary Open Angle Glaucoma\|Intraocular Pressure	Sooft Italia	April 2009	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Choose Your Country or Region

By Signaling Pathways

By product type

Forskolin

Cited by 8 Publications

2 Customer Reviews

Purity & Quality Control

Choose Selective cAMP Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Forskolin SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

cAMP Signaling Pathway Map

Choose Your Country or Region

By Signaling Pathways

By product type

Forskolin

Cited by 8 Publications

2 Customer Reviews

Purity & Quality Control

Choose Selective cAMP Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Forskolin SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

cAMP Signaling Pathway Map

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)